# Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

> **NCT05500807** · PHASE1 · RECRUITING · sponsor: **Bleeding and Clotting Disorders Institute Peoria, Illinois** · enrollment: 40 (estimated)

## Conditions studied

- Von Willebrand Disease, Type 3
- Concomitant VWD and Hemophilia

## Interventions

- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT05500807
- **Lead sponsor:** Bleeding and Clotting Disorders Institute Peoria, Illinois
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2027-06
- **Final completion:** 2028-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05500807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05500807, "Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05500807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*